[1] 吴彦青, 郭玉红, 刘清泉.中医药干预多发性硬化的作用机制与治疗研究展望[J].世界中医药, 2017, 12(4):735-737. [2] 王春琛, 陈志刚, 马昕宇. 金针王乐亭经验方治疗缓解期复发缓解型多发性硬化8例的临床观察[J]. 世界中医药, 2017, 12(9):2114-2117. [3] COMPSTON A,COLES A. Multiple sclerosis[J]. Lancet, 2008, 372(648):1502-1517. [4] LUBLIN F D, REINGOLD S C,COHEN J A,et al. Defining the clinical course of multiple sclerosis:The 2013 revisions[J]. Neurology, 2014, 83(3):278-286. [5] WINGERCHUK D M,CARTER J L. Multiple sclerosis:current and emerging disease-modifying therapies and treatment strategies[J]. Mayo Clin Proc,2014, 89(2):225-240. [6] DE LAGO E, MORENO-MARTET M, CABRANES A, et al. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects[J]. Neuropharmacology, 2012, 62(7):2299-2308. [7] RUSKAMO S, CHUKHLIEB M, VAHOKOSKI J, et al. Juxtanodin is an intrinsically disordered F-actin-binding protein[J]. Sci Rep, 2012, 2:899. [8] ZHANG B, CAO Q, GUO A, et al. Juxtanodin:an oligodendroglial protein that promotes cellular arborization and 2',3'-cyclic nucleotide-3'-phosphodiesterase trafficking[J]. Proc Natl Acad Sci U S A, 2005, 102(32):11527-11532. [9] MATSUSHIMA G K, MORELL P. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system[J]. Brain Pathol,2001,11(1):107-116. [10] WISSEL J, HAYDN T,MVLLER J,et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain:A double-blind placebo-controlled cross-over trial[J]. J Neurol,2006,253(10):1337-1341. [11] 王颖.丁苯酞通过抑制PGAM5介导的坏死性凋亡对实验性自身免疫性脑脊髓炎小鼠发挥保护作用[D].石家庄:河北医科大学, 2018. [12] DI F P, REINDL M, BERGER T. New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseases[J]. Multiple Sclerosis Related Disord, 2018, 22:35-37. [13] POOREBRAHIM M, ASGHARI M, ABAZARI M F,et al. Immunomodulatory effects of a rationally designed peptide mimetic of human IFNβ in EAE model of multiple sclerosis[J]. Prog Neuro-Psychopharmacol Biol Psychiat, 2018, 82:49-61. [14] 王璐,杨瀚宇,臧彩霞,等. CXCR2在多发性硬化症中的作用和机制研究进展[J]. 中国新药杂志, 2018, 27(22):2630-2635. [15] PASQUINI L A, MILLET V, HOYOS H C, et al. Galectin-3 drives oligodendrocyte differentiation to control myelin integrity and function[J]. Cell Death Differ, 2011, 18(11):1746-1756. [16] NARAYAN R N, FORSTHUBER T, STVVE O. Emerging drugs for primary progressive multiple sclerosis[J]. Expert Opin Emerg Drugs, 2018,23(2):97-110. [17] BROCKSCHNIEDER D, SABANAY H, RIETHMACHER D,et al. Ermin, a myelinating oligodendrocyte-specific protein that regulates cell morphology[J]. J Neurosci, 2006, 26(3):757-762. [18] KIPP M, CLARNER T,DANG J,et al.The cuprizone animal model:new insights into an old story[J]. Acta Neuropatholo, 2009, 118(6):723-736. [19] STEELMAN A J, THOMPSON J P, LI J. Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication[J]. Neurosci Res, 2012, 72(1):32-42. [20] 穆建坤, 刘宏亮, 姚忠祥,等. 大麻素WIN55,212-2对双环己酮草酰二腙诱导的脱髓鞘模型髓鞘修复作用的研究[J]. 第三军医大学学报, 2013, 35(11):1129-1132. [21] MARCIN CZEPIEL,ERIK BODDEKE,SJEF COPRAY,等. 人类少突胶质细胞在髓鞘修复中的作用[J]. 神经损伤与功能重建, 2015,10(2):138-138. [22] WANG T, JIA L, YANG G, et al. Identification of Juxtanodin promoter and its transcriptional regulation during the ATRA-induced differentiation of C6 cells[J]. Mol Cell Biochem, 2011, 350(1/2):177-183. |